BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18:1392-1398. [PMID: 14675268 DOI: 10.1046/j.1440-1746.2003.03190.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Review of Anti-infective Therapy 2014;3:863-70. [DOI: 10.1586/14787210.3.6.863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
2 Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;CD003244. [PMID: 17443524 DOI: 10.1002/14651858.cd003244.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 55] [Article Influence: 1.5] [Reference Citation Analysis]
3 Ashida K, Kinoshita Y, Hongo M; The Japan Rabeprazole Study Group for NERD. Acid-Suppressive Effect of Rabeprazole 5 mg and 10 mg Once Daily by 24-Hour Esophageal pH Monitoring in Patients with Non-erosive Reflux Disease in Japan: A Multicenter, Randomized, Parallel-Group, Double-Blind Pharmacodynamic Study. Dig Dis Sci 2011;56:2333-42. [DOI: 10.1007/s10620-011-1583-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Yamashita H, Ashida K, Kawaguchi S, Fukuchi T, Nagatani Y, Hasegawa T, Koga H, Eguchi T, Ubukata S, Tanaka T, Ito D. The pathogenesis of persistent non-erosive reflux disease treated with proton-pump inhibitors as measured with the Symptom Index. Esophagus 2015;12:50-6. [DOI: 10.1007/s10388-014-0452-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Lee YS, Choi SH, Son YI, Park YH, Kim SY, Nam SY. Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol. 2011;268:863-869. [PMID: 21221621 DOI: 10.1007/s00405-010-1475-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
7 Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2012;10:338-345; quiz e39-40. [PMID: 22178462 DOI: 10.1016/j.cgh.2011.12.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
8 Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213-224. [PMID: 21083596 DOI: 10.1111/j.1365-2036.2010.04508.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
9 Edwards SJ, Lind T, Lundell L, Das R. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials. Alimentary Pharmacology & Therapeutics 2009;30:547-56. [DOI: 10.1111/j.1365-2036.2009.04077.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
10 Hamamoto N, Hashimoto T, Adachi K, Hirakawa K, Ishihara S, Inoue H, Taniura H, Niigaki M, Sato S, Kushiyama Y, Suetsugu H, Miyake T, Kinoshita Y. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. J Gastroenterol Hepatol 2005;20:281-6. [PMID: 15683433 DOI: 10.1111/j.1440-1746.2004.03546.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26:69-77. [PMID: 17555423 DOI: 10.1111/j.1365-2036.2007.03350.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
12 Kusano M, Shirai N, Yamaguchi K, Hongo M, Chiba T, Kinoshita Y; The Acid-Related Symptom (ARS) Research Group. It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients. Dig Dis Sci 2008;53:3082-94. [DOI: 10.1007/s10620-008-0290-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
13 Dadabhai A, Friedenberg FK. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf 2009;8:119-26. [PMID: 19236223 DOI: 10.1517/14740330802622892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
14 Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8-22. [PMID: 18171339 DOI: 10.1111/j.1440-1746.2007.05249.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 8.1] [Reference Citation Analysis]
15 Moayyedi P, Santana J, Khan M, Preston C, Donnellan C; Cochrane Upper GI and Pancreatic Diseases Group. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd003244.pub3] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Oda K, Iwakiri R, Hara M, Watanabe K, Danjo A, Shimoda R, Kikkawa A, Ootani A, Sakata H, Tsunada S. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci. 2005;50:1921-1926. [PMID: 16187198 DOI: 10.1007/s10620-005-2962-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang ZB, Chen LL, You XD. Efficacy of esomeprazole combined with hydrotalcite and mosapride in treatment of refractory gastroesophageal reflux disease. Shijie Huaren Xiaohua Zazhi 2007; 15(8): 901-904 [DOI: 10.11569/wcjd.v15.i8.901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Savarino E, Tutuian R, Zentilin P, Dulbecco P, Pohl D, Marabotto E, Parodi A, Sammito G, Gemignani L, Bodini G, Savarino V. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: Study using combined impedance-pH off therapy. Am J Gastroenterol. 2010;105:1053-1061. [PMID: 19997095 DOI: 10.1038/ajg.2009.670] [Cited by in Crossref: 136] [Cited by in F6Publishing: 128] [Article Influence: 10.5] [Reference Citation Analysis]
20 Furuta K, Adachi K, Ohara S, Morita T, Tanimura T, Koshino K, Kinoshita Y. Relationship between the Acid-Inhibitory Effects of Two Proton Pump Inhibitors and CYP2C19 Genotype in Japanese Subjects: A Randomized Two-Way Crossover Study. J Int Med Res 2010;38:1473-83. [DOI: 10.1177/147323001003800430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
21 Conchillo JM, Schwartz MP, Selimah M, Samsom M, Sifrim D, Smout AJ. Acid and non-acid reflux patterns in patients with erosive esophagitis and non-erosive reflux disease (NERD): a study using intraluminal impedance monitoring. Dig Dis Sci. 2008;53:1506-1512. [PMID: 17934853 DOI: 10.1007/s10620-007-0059-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
22 Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013;38:1129-1137. [PMID: 24099474 DOI: 10.1111/apt.12492] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
23 Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract 2013;2013:327571. [PMID: 24106498 DOI: 10.1155/2013/327571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Shimatani T, Sugimoto M, Nishino M, Adachi K, Furuta K, Ito M, Kurosawa S, Manabe N, Mannen K, Hongo M, Chiba T, Kinoshita Y; the Acid-Related Symptom Research (ARS) Group. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring: Intraesophageal 2-channel pH monitoring. Journal of Gastroenterology and Hepatology 2012;27:899-906. [DOI: 10.1111/j.1440-1746.2011.06975.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
25 Kinoshita Y, Hongo M; Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol 2012;107:522-30. [PMID: 22433921 DOI: 10.1038/ajg.2012.19] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
26 Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:327571. [PMID: 24106498 DOI: org/10.1155/2013/327571] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kinoshita Y. Review article: treatment for gastro-oesophageal reflux disease - lifestyle advice and medication: REVIEW: GERD - LIFESTYLE AND MEDICATION. Alimentary Pharmacology & Therapeutics 2004;20:19-23. [DOI: 10.1111/j.1365-2036.2004.02223.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
28 Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment Pharmacol Ther Symp Series 2006;2:340-50. [DOI: 10.1111/j.1746-6342.2006.00065.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
29 Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131-137. [PMID: 17245209 DOI: 10.1097/01.mcg.0000225631.07039.6d] [Cited by in Crossref: 169] [Cited by in F6Publishing: 152] [Article Influence: 11.3] [Reference Citation Analysis]
30 Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011; 17(14): 1858-1865 [PMID: 21528060 DOI: 10.3748/wjg.v17.i14.1858] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
31 Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012;6:423-435. [PMID: 22928894 DOI: 10.1586/egh.12.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
32 Chen Y, Wang F, Jiang Y, Wang C, Yao L, Wu P, Tong Y, Sun H, Xu S. The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease. Gastroenterol Res Pract 2013;2013:419375. [PMID: 23533388 DOI: 10.1155/2013/419375] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]